Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Fleischmann, Roy; L. Pangan, Aileen; Song, In‐Ho; Mysler, Eduardo; Bessette, Louis; Peterfy, Charles; Durez, Patrick; J. Ostor, Andrew; Li, Yihan; Zhou, Yijie; A. Othman, Ahmed; C. Genovese, Mark

doi:10.1002/art.41032

Public

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

Shared by NobleBlocks on Aug 28, 2019 • 12:00 AM UTC

Authors:

Roy Fleischmann

Aileen L. Pangan

In‐Ho Song

Abstract

Objective To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis ( RA ) who have experienced an inadequate response to methotrexate ( ...

Discussions